Product Information
EZETIMIBE-SIMVASTATIN 10-40 MG is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $0.2368 per EA under NDC 43598074305. Its NADAC has been published 400 times since Dec 26, 2018.
FDA first approved this application on Apr 26, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 40 mg/1; mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
43598074305
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
EZETIMIBE; SIMVASTATINApproval Type
Generic (ANDA)
FDA Application
ANDA200909FDA Approved
4/26/2017
TE Code
AB
On Market Since
11/20/2018
Pharmacological Classes
Price Statistics
The NADAC for EZETIMIBE-SIMVASTATIN 10-40 MG has been published 400 times since Dec 26, 2018, and over the history we have for it it has declined 89.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2368 per EA |
|---|---|
| All-time high | $2.1525 (Jan 16, 2019) |
| All-time low | $0.2368 (Aug 19, 2026) |
| 52-week high | $0.5024 |
| 52-week low | $0.2368 |
| Median price | $0.5741 |
| Average price | $0.9034 |
| Largest weekly change | +78.2% (May 18, 2022) |
| Weeks tracked | 400 |
| Tracking since | Dec 26, 2018 |
1W
N/A
1M
N/A
3M
-36.3%
6M
-31.7%
1Y
-52.9%
3Y
-56.4%
5Y
-67.0%
All
-89.0%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 23% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ezetimibe and Simvastatin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dietary Cholesterol Absorption Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EZETIMIBE-SIMVASTATIN 10-40 MG?
The current National Average Drug Acquisition Cost (NADAC) for EZETIMIBE-SIMVASTATIN 10-40 MG, manufactured by Dr. Reddy's Laboratories Inc., is $0.2368 per EA (NDC 43598074305), effective Aug 19, 2026.
How has the price of EZETIMIBE-SIMVASTATIN 10-40 MG changed over time?
Over the history we have for it, the NADAC for EZETIMIBE-SIMVASTATIN 10-40 MG has declined 89.0%. It has been tracked across 400 weekly CMS publications since Dec 26, 2018.
What are the highest and lowest recorded NADAC prices for EZETIMIBE-SIMVASTATIN 10-40 MG?
Since Dec 26, 2018, the NADAC for EZETIMIBE-SIMVASTATIN 10-40 MG has ranged from a low of $0.2368 (Aug 19, 2026) to a high of $2.1525 (Jan 16, 2019), with a median of $0.5741 per EA.
Are there cheaper alternatives to EZETIMIBE-SIMVASTATIN 10-40 MG?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EZETIMIBE-SIMVASTATIN 10-40 MG, is $0.1830 per EA — about 23% below EZETIMIBE-SIMVASTATIN 10-40 MG.
Who manufactures EZETIMIBE-SIMVASTATIN 10-40 MG?
EZETIMIBE-SIMVASTATIN 10-40 MG (NDC 43598074305) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.